Optical Coherence Tomography as a Measure of Neuroprotection in Patients With Relapsing-Remitting Multiple Sclerosis Receiving Natalizumab or Interferon Beta-1a.
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 04 Jun 2015
At a glance
- Drugs Interferon beta-1a; Natalizumab
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms PRTOECT
- Sponsors Biogen
- 05 Jan 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 24 Oct 2008 New trial record.